Nanox.AI vs TeraRecon (2026)
One of these finds things nobody asked about, and the other is a platform findings can travel on. Nanox.AI, formerly Zebra Medical Vision, analyzes CT scans taken for other reasons to surface findings such as vertebral compression fractures and coronary calcium, with a clearance portfolio built over years and a listed parent whose filings describe the business. TeraRecon is vendor neutral advanced visualization with an AI Framework that runs its own algorithms, third party algorithms and a site's in house models through one PACS integration. The question opportunistic screening raises, and neither vendor answers, is who carries the follow up: a finding surfaced from a scan taken for something else creates work, and that cost lands on the health system.
- Opportunistic population health: it analyzes CT scans taken for another reason to surface findings nobody was looking for.
- A clearance portfolio built over years across several anatomical findings.
- As a subsidiary of a listed parent, its business is described in filed disclosures.
- Vendor neutral visualization is the base: TeraRecon AV reads CT, MR and other modalities in 2D, 3D and 4D, independent of scanner or archive vendor, at more than 2,000 hospitals by its own count.
- One integration for many models: the AI Framework runs TeraRecon's own algorithms, third party algorithms and a site's in house models through one PACS connection, with physicians accepting or rejecting results before they reach the report.
- Conformance published: indications for use and IHE, DICOM and HL7 conformance statements are public, and ISO 27001:2022 certification was announced in 2023.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Nanox.AI and TeraRecon are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Nanox.AI | TeraRecon |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2014 | Not recorded |
| Headquarters | Neve Ilan, Israel | Fremont, California |
| Website | nanox.vision | terarecon.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
TeraRecon
-
Product / capability
TeraRecon released TeraRecon Neuro, a new software package designed to assist clinicians in diagnosing and treating neurovascular emergencies such as stroke.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Imaging AI business of Nasdaq listed Nano-X Imaging, formerly Zebra Medical Vision, acquired in November 2021. Its solutions analyze CT scans already acquired for other reasons to surface undiagnosed chronic disease: HealthOST for vertebral height loss and bone mineral density, HealthCCSng for coronary artery calcium on non gated chest CT, and HealthFLD for liver density in fatty liver disease.
Source: AI Health Index, August 2026
TeraRecon, a ConcertAI company, sells advanced visualization and AI workflow software for radiology and cardiology. TeraRecon AV (registered as Intuition outside the US) is vendor neutral 2D, 3D and 4D visualization, measurement and reporting across CT, MR and other modalities, with modules for cardiac, structural heart, perfusion and neuro work.
Source: AI Health Index, August 2026
Questions buyers ask
How do Nanox.AI and TeraRecon work with the EHR?
For Nanox.AI, the AI page describes integration with PACS, record and reporting systems, and record integration to streamline patient care, and names Corewell Health, Atlantic Health System, Jefferson Einstein Hospital, Rabin Medical Center and NHS hospitals as users. The HealthVCF summary describes findings shown in a standalone worklist application.
TeraRecon's regulatory page links IHE integration statements, a DICOM conformance statement and an HL7 conformance statement for its connector. The AI Framework shares results with the site's reporting system by DICOM and HL7 and integrates with PACS once for many algorithms. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Nanox.AI and TeraRecon priced and sold?
In Nanox.AI's case, the parent, a Nasdaq listed company, describes its business model in securities filings, including software as a service billing and a pay per scan model for its imaging hardware. Whether the AI solutions are licensed per scan, per site or per population is not stated, and the answer changes the cost of running a screening program across a whole archive.
The site shows how the offer is structured: TeraRecon AV (Intuition) for advanced visualization, TR Neuro, DETECT and the AI Framework, sold through a demo request and delivered installed or as a cloud service with professional services for integration. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Nanox.AI and TeraRecon handle patient data?
With Nanox.AI, the solutions read CT studies acquired for unrelated reasons, at archive scale, so most patients whose scans are analyzed will not know a second analysis occurred. There is no published retention period, de identification standard or statement on whether analyzed imaging trains the models.
The footer links a privacy policy and a Data Privacy Framework policy for EU to US transfers, and a RACI matrix for TeraRecon Cloud services, none of which sets out what happens to imaging. The Eureka indication says the platform sends images to hosted external systems for processing according to routing rules the user defines. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Nanox.AI and TeraRecon cover?
For Nanox.AI, the liver solution's validation is not described on the AI page.
TeraRecon says more than 2,000 hospitals use its software worldwide. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Radiology & Imaging AI page.
Nanox.AI's record has not yet been reviewed on this site, so its side of this page rests on the build record; it publishes no health privacy commitment, data governance framework or subgroup analysis. TeraRecon publishes no clearance numbers or performance figures for its own AI devices, and third party algorithms on its platform carry their own status. Neither publishes pricing.